Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer

BACKGROUND: The integration of residual cancer burden (RCB) and post‐treatment Ki67 as residual proliferative cancer burden (RPCB) has been proposed as a stronger predictor of long‐term outcome in unselected patients with breast cancer (BC) undergoing neoadjuvant chemotherapy (NACT), as compared wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Miglietta, Federica, Dieci, Maria Vittoria, Tsvetkova, Vassilena, Griguolo, Gaia, Vernaci, Grazia, Menichetti, Alice, Faggioni, Giovanni, Giarratano, Tommaso, Mioranza, Eleonora, Genovesi, Elisa, Cumerlato, Enrico, Bottosso, Michele, Saibene, Tania, Michieletto, Silvia, Lo Mele, Marcello, Conte, Pierfranco, Guarneri, Valentina
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Breast Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485331/
https://ncbi.nlm.nih.gov/pubmed/32618068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0201
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados